GALWAY, Ireland, April 21, 2026 — InVera Medical, a medical device company focused on advancing minimally-invasive technologies for Chronic Venous Disease, today announced 12-month results from its pilot clinical study of the InVera Infusion Device designed to treat Chronic Venous Disease (CVD). The results, presented today by Dr. Lowell Kabnick, Past President of the American Venous Forum (AVF) and head of InVera’s Medical Advisory Board (MAB), at the International Charing Cross Symposium in London, demonstrated statistically significant improvements in patient symptoms, high procedural efficacy, and an excellent safety profile.
The pilot study enrolled 10 patients with Chronic Venous Disease (CEAP classification C2-C4) requiring ablation of the Great Saphenous Vein (GSV) due to abnormal reflux, who were followed for one year. The study used a strict protocol which prohibited adjunctive procedures or tributary vein management to minimize confounding factors.